Dr Falk Pharma (Germany)

Recent papers from Dr Falk Pharma (Germany)

1. The regulatory landscape for clinical metagenomics-based diagnostics in Europe: a critical reviewJournal of Microbiological Methods · 2026
2. Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac diseaseBMC Medicine · 2026
3. Time to eosinophilic oesophagitis diagnosis for patients presenting with upper gastrointestinal symptoms in primary and secondary careFrontline Gastroenterology · 2026
4. Real-world-data on efficacy and safety of topical budesonide therapy (orodispersible tablet) in induction and maintenance therapy in adult patients with active eosinophilic esophagitisTherapeutic Advances in Gastroenterology · 2025
5. Chicken Manure as a Sustainable Bile Acid Source for Biotechnological ApplicationsMicrobial Biotechnology · 2025
6. Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension StudyClinical Gastroenterology and Hepatology · 2024
7. Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac diseaseNature Immunology · 2024
8. Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRC.Journal of Clinical Oncology · 2024
9. A New Method to Evaluate Lower Esophageal Distension Capacity in Eosinophilic Esophagitis by Using Functional Lumen Imaging Probe (EndoFLIP™)Diagnostics · 2024
10. Esophageal Candidiasis Is Strongly Associated With Treatment Response to Topical Steroids in Eosinophilic Esophagitis and Could Be a Marker of AdherenceGastro Hep Advances · 2024
11. Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR StudyBreast Care · 2023
12. Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitisUnited European Gastroenterology Journal · 2023
13. Increasing the collection flow rate to 2 mL/min is effective and reduces the procedure time in off‐line photopheresisTransfusion · 2023
14. The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug TreatmentInternational Journal of Molecular Sciences · 2023
15. Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRCAnticancer Research · 2022
16. Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority TrialJournal of Crohn s and Colitis · 2022
17. Characterization of Eosinophilic Esophagitis From the European Pediatric Eosinophilic Esophagitis Registry (pEEr) of ESPGHANJournal of Pediatric Gastroenterology and Nutrition · 2022
18. Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo‐controlled multicentre trialUnited European Gastroenterology Journal · 2021
19. A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac DiseaseNew England Journal of Medicine · 2021
20. Usefulness of Peripheral Blood Monocyte Count to Predict Relapse in Patients With Inflammatory Bowel Disease: A Prospective Longitudinal Cohort Study.Revista Española de Enfermedades Digestivas · 2021